| Chronic Urticaria or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2019 |
| Publication Date |
Apr 2012 |
| Publisher |
GlobalData |
| Product Type |
Report |
| Pages |
67 |
| Single User License |
$
3995.00 |
| Site User License |
$
7990.00 |
| Corporate User License |
$
11985.00 |
|
|
Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase. |
Chronic Urticaria or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Chronic Urticaria or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Chronic Urticaria Or Hives Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Urticaria Or Hives Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Urticaria Or Hives Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Chronic Urticaria Or Hives Therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) Chronic Urticaria therapeutics market revenue data for 2006–2011, and 2011–2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Chronic Urticaria Or Hives Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Urticaria Or Hives Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Chronic Urticaria Or Hives Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Chronic Urticaria Or Hives Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Urticaria Or Hives Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Chronic Urticaria Or Hives Therapeutics market landscape? – Identify, understand and capitalize.
Companies MentionedF. Hoffmann-La Roche Ltd.
Biofrontera AG (Subsidiary of DNAPrint Genomics, Inc.).
Sun Pharmaceutical Industries Limited.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 CU Therapeutics - Introduction 7
2.1 Overview 7
2.2 Etiology 7
2.3 Pathophysiology 8
2.4 Epidemiology 9
2.5 Symptoms 9
2.6 Diagnosis 10
2.7 Treatment and Management Pattern 11
2.8 GlobalData Report Guidance 14
3 CU Therapeutics - Market Characterization 15
3.1 CU Therapeutics Market Size (2006-2011) – Global 15
3.2 CU Therapeutics Market Forecast (2011-2019) – Global 16
3.3 CU Therapeutics Market Size (2006-2011): The US 17
3.4 CU Therapeutics Market Forecast (2011-2019): The US 18
3.5 CU Therapeutics Market (2006-2011): France 19
3.6 CU Therapeutics Market Forecast (2011-2019): France 20
3.7 CU Therapeutics Market (2006-2011): Germany 21
3.8 CU Therapeutics Market Forecast (2011-2019): Germany 22
3.9 CU Therapeutics Market (2006-2011): Italy 23
3.10 CU Therapeutics Market Forecast (2011-2019): Italy 24
3.11 CU Therapeutics Market (2006-2011): Spain 25
3.12 CU Therapeutics Market Forecast (2011-2019): Spain 26
3.13 CU Therapeutics Market (2006-2011): The UK 27
3.14 CU Therapeutics Market Forecast (2011-2019): The UK 28
3.15 CU Therapeutics Market (2006-2011): Japan 29
3.16 CU Therapeutics Market Forecast (2011-2019): Japan 30
3.17 Drivers and Barriers for the CU Therapeutics Market 31
3.17.1 Drivers for the CU Therapeutics Market 31
3.17.2 Barriers for the CU Therapeutics Market 31
3.18 Opportunity and Unmet Need Analysis 32
3.19 Key Takeaway 33
4 CU Therapeutics - Competitive Assessment 34
4.1 Overview 34
4.2 Strategic Competitor Assessment 34
4.3 Product Profile for the Major Marketed Products in the CU Therapeutics Market 35
4.3.1 Allegra (fexofenadine hydrochloride) 35
4.3.2 Xyzal (levocetirizine dihydrochloride) 36
4.3.3 Clarinex (desloratadine) 37
4.3.4 Cetirizine 38
4.3.5 Bilastine 39
4.4 Key Takeaway 41
5 CU Therapeutics - Pipeline Assessment 42
5.1 Overview 42
5.2 Strategic Pipeline Assessment 42
5.3 CU Therapeutics Pipeline – Pipeline by Phases of Development 42
5.3.1 CU Therapeutics – Phase III Pipeline 43
5.3.2 CU Therapeutics – Phase II Pipeline 43
5.4 CU Therapeutics Market – Clinical Pipeline by Mechanism of Action 44
5.5 Technology Trends Analytical Framework 45
5.6 CU Therapeutics – Promising Drugs Under Clinical Development 46
5.7 Molecule Profile for Promising Drugs Under Clinical Development 46
5.7.1 Xolair (omalizumab) 46
5.8 Key Takeaway 47
6 CU Therapeutics - Clinical Trials Mapping 48
6.1 Clinical Trials by Region/Country (the US, EU5, and Japan) 48
6.2 Clinical Trials by Phase 49
6.3 Clinical Trials by Trial Status 50
6.4 Clinical Trials by Overall Sponsors 51
6.5 Prominent Sponsors 52
6.6 Key Companies Participating in Therapeutics Clinical Trials 53
7 CU Therapeutics - Strategic Assessment 54
7.1 Key Events Impacting the Future Market 54
7.2 CU Therapeutics: Implications for Future Market Competition 55
8 CU Therapeutics - Future Players 56
8.1 Introduction 56
8.2 Company Profiles 57
8.2.1 F. Hoffmann-La Roche Ltd. 57
8.2.2 Biofrontera AG (Subsidiary of DNAPrint Genomics, Inc.). 58
8.2.3 Sun Pharmaceutical Industries Limited. 58
9 CU Therapeutics - Licensing and Partnership Deals 61
10 CU Therapeutics - Appendix 62
10.1 Market Definitions 62
10.2 Abbreviations 62
10.3 METHODOLOGY 63
10.3.1 Coverage 63
10.3.2 Secondary Research 63
10.3.3 Forecasting 63
10.3.4 Primary Research 66
10.3.5 Expert Panel Validation 66
10.4 Contact Us 66
10.5 Disclaimer 66
10.6 Bibliography 67
List of Tables1.1 List of Tables
Table 1: Features of Common Types of Urticaria 7
Table 2: First Line of Treatment in CU 12
Table 3: Second Line of Treatment in CU 12
Table 4: Rarely used drugs in CU 13
Table 5: CU Therapeutics Market, Global, Revenue ($m), 2006-2011 15
Table 6: CU Therapeutics Market, Global, Forecast ($m), 2011-2019 16
Table 7: CU Therapeutics Market, the US, Revenue ($m), 2006-2011 17
Table 8: CU Therapeutics Market, the US, Forecast ($m), 2011-2019 18
Table 9: CU Therapeutics Market, France, Revenue ($m), 2006-2011 19
Table 10: CU Therapeutics Market, France, Forecast ($m), 2011-2019 20
Table 11: CU Therapeutics Market, Germany, Revenue ($m), 2006-2011 21
Table 12: CU Therapeutics Market, Germany, Forecast ($m), 2011-2019 22
Table 13: CU Therapeutics Market, Italy, Revenue ($m), 2006-2011 23
Table 14: CU Therapeutics Market, Italy, Forecast ($m), 2011-2019 24
Table 15: CU Therapeutics Market, Spain, Revenue ($m), 2006-2011 25
Table 16: CU Therapeutics Market, Spain, Forecast ($m), 2011-2019 26
Table 17: CU Therapeutics Market, the UK, Revenue ($m), 2006-2011 27
Table 18: CU Therapeutics Market, the UK, Forecast ($m), 2011-2019 28
Table 19: CU Therapeutics Market, Japan, Revenue ($m), 2006-2011 29
Table 20: CU Therapeutics Market, Japan, Forecast ($m), 2011-2019 30
Table 21: CU Therapeutics – Strategic Competitor Assessment, 2011 34
Table 22: Changes in the First Week of a Clinical Trial in Patients with Chronic Idiopathic Urticaria 38
Table 23: Major Marketed Products Analysis in the CU Therapeutics Market, 2011 40
Table 24: CU Therapeutics Market – Phase III Pipeline, 2011 43
Table 25: CU Therapeutics Market – Phase II Pipeline, 2011 43
Table 26: Chronic Urticaria – Most Promising Drugs Under Clinical Development, 2011 46
Table 27: CU Therapeutics Market, Clinical Trials by Region, 2011 48
Table 28: CU Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 49
Table 29: CU Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 50
Table 30: CU Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 51
Table 31: CU Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 52
Table 32: CU Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2011 53
Table 33: CU Therapeutics Market – Clinical Pipeline by Company, 2011 56
Table 34: Pipeline Molecules 2011 57
Table 35: Pipeline Products 2011 58
Table 36: Pipeline Product 2011 60
Table 37: Licensing and Partnership Deals 61
List of Figures1.2 List of Figures
Figure 1: Mast Cell Degranulation in CU 9
Figure 2: Diagnosis Algorithm for CU 10
Figure 3: Diagnosis Algorithm for CU 11
Figure 4: CU Therapeutics Market, Global, Revenue ($m), 2006-2011 15
Figure 5: CU Therapeutics Market, Global, Forecast ($m), 2011-2019 16
Figure 6: CU Therapeutics Market, the US, Revenue ($m), 2006-2011 17
Figure 7: CU Therapeutics Market, the US, Forecast ($m), 2011-2019 18
Figure 8: CU Therapeutics Market, France, Revenue ($m), 2006-2011 19
Figure 9: CU Therapeutics Market, France, Forecast ($m), 2011-2019 20
Figure 10: CU Therapeutics Market, Germany, Revenue ($m), 2006-2011 21
Figure 11: CU Therapeutics Market, Germany, Forecast ($m), 2011-2019 22
Figure 12: CU Therapeutics Market, Italy, Revenue ($m), 2006-2011 23
Figure 13: CU Therapeutics Market, Italy, Forecast ($m), 2011-2019 24
Figure 14: CU Therapeutics Market, Spain, Revenue ($m), 2006-2011 25
Figure 15: CU Therapeutics Market, Spain, Forecast ($m), 2011-2019 26
Figure 16: CU Therapeutics Market, the UK, Revenue ($m), 2006-2011 27
Figure 17: CU Therapeutics Market, the UK, Forecast ($m), 2011-2019 28
Figure 18: CU Therapeutics Market, Japan, Revenue ($m), 2006-2011 29
Figure 19: CU Therapeutics Market, Japan, Forecast ($m), 2011-2019 30
Figure 20: Opportunity and Unmet Need in the CU Therapeutics Market, 2011 33
Figure 21: CU Therapeutics Pipeline by Phase of Clinical Development, 2011 42
Figure 22: CU Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011 44
Figure 23: Technology Trends Analytic Framework for the CU Therapeutics Pipeline, 2011 45
Figure 24: Technology Trends Analytic Framework for the CU Therapeutics Pipeline, 2011 46
Figure 25: CU Therapeutics Market – Clinical Trials by Region, 2011 48
Figure 26: CU Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 49
Figure 27: CU Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 50
Figure 28: CU Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 51
Figure 29: CU Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 52
Figure 30: CU Therapeutics Market, Global, Clinical Trials by Top Companies, 2011 53
Figure 31: Drivers and Barriers of the CU Therapeutics Market 54
Figure 32: Implications for Future Market Competition in the CU Therapeutics Market, 2011 55
Figure 33: GlobalData Market Forecasting Model 65
| Title |
Date |
Price |
|
|
Jan 2013 |
$2000.00 |
|
|
Oct 2009 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
| 2011 U.S. Offices of Dentists Industry Report |
| By Barnes Reports |
| The Offices of Dentists Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2011 current and 2012 f ...Read More
|
|
Oct 2010 |
$149.00 |
|
|
May 2011 |
$149.00 |
|
|
Oct 2010 |
$149.00 |
|
|
May 2011 |
$149.00 |
|
|
Apr 2011 |
$149.00 |
|
|
Oct 2010 |
$149.00 |
|
|
May 2011 |
$149.00 |
|
| |
|
|
|
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
|
|
|
| |
|
| |
|
|
|
